



# CardioMag Imaging<sup>TM</sup>



CardioMag Imaging<sup>TM</sup>, Inc.  
450 Duane Avenue  
Schenectady, NY 12304  
Phone (518) 381-1000  
Fax (518) 381-4400  
cardiomag@cardiomag.com

**FOR IMMEDIATE RELEASE**  
Schenectady, NY, October 1, 2003

**Contact: Carl H. Rosner**  
**President and CEO**  
**(518) 381-1000**

## **CardioMag Imaging<sup>TM</sup> Brings Novel Heart-Health Scanning<sup>TM</sup> Device to China**

### **Featured at Grand Opening of Major New Hospital in Tianjin**

Worldwide recognition of a new heart-health diagnostic technology has been expanded again with the installation of a CardioMag Imaging<sup>TM</sup>, Inc. (CMI<sup>TM</sup>) system in Tianjin, China.

The new cardiovascular diagnostic technique – described by physicians as a “totally safe, non-contact, highly sensitive, and non-invasive approach to early diagnosis of heart problems” – will serve thousands of patients at the new Tianjin International Cardiovascular Hospital.

Positive reports from selected, similar installations in the U.S., Germany, and Italy are providing a solid basis for the expected early FDA approval and certification of CMI's Magnetocardiography (MCG) heart-scanning technology.

Tianjin, population over ten million, is one of China's major port-cities, serving as the closest entryway to the capital city of Beijing. The city is the center of the Tianjin Economic Development Area (TEDA). The new, ultra-modern TEDA International Cardiovascular Hospital has selected and purchased CardioMag Imaging Inc.'s unique heart-scanning system as a key component of its 700 bed state-of-the-art cardiovascular diagnostic and treatment center.

The grand opening last week, of the Tianjin hospital, was attended by over 1,000 dignitaries, physicians, and healthcare providers from China and countries around the world.

Dr. Liu Xiaocheng, a renowned cardiologist and President of the TEDA hospital, said he believes the basis of CMI's technology provides a truly revolutionary approach to letting cardiologists diagnose heart disorders “better, faster, and less expensively.” This view is also shared by Dr. Chen, Director of Electrophysiology at the hospital, who looks forward to the acquisition by the hospital of the next generation of CMI's MCG system, already under test, since it will expand his ability to specifically study life-threatening arrhythmias.

- more -

During the hospital's grand-opening day, CMI's non-invasive heart-scan examinations were conducted on a wide variety of individuals, providing impressive results from the rapid, non-invasive and pain-free tests lasting only 15 minutes or less.

Dr. Liu had arranged for the CMI system purchase after seeing a demonstration in Schenectady earlier this year, when he and his hospital executives were visiting local industrial laboratories and hospitals while attending a 3-week course given by the MBA program in Health Administration at the Graduate College of Union University.

Carl H. Rosner, president of CardioMag Imaging, says the Schenectady-based company is focused upon increasing its ability to provide lifesaving and medical-cost-containing solutions for the health-care community. According to Rosner, the growing CMI team is rapidly creating new design, manufacturing, and marketing approaches to provide "innovative imaging and medical diagnostic devices."

**CardioMag Imaging™, Inc.**, a privately held company formed in 1999 to transition results from over 30 years of worldwide MCG research and development into commercially useful and attractive cardiac diagnostic products, based upon SQUID (Superconducting Quantum Interference Device) sensors, is positioning itself to provide lifesaving and medical cost containment solutions to the cardiac health care community by designing, manufacturing and marketing innovative imaging and medical diagnostic devices for early detection and follow-up treatment of heart disease.

**Safe Harbor Statement:** The statements presented in this press release which are not historical fact are forward looking statements which involve various important assumptions, risks, uncertainties and other factors set forth here, including but not limited to, obtaining FDA approval, market acceptance, insurance companies reimbursement policies on particular diagnostic applications and the growth of customer acceptance.

####